Who Owns Sandoz?

Sandoz was founded in 1886 by Edmond Sandoz in Basel, Switzerland. The company began as a pharmaceutical manufacturer focused on developing and producing medicines. Edmond Sandoz's vision was to create high-quality pharmaceutical products that would serve patients globally, establishing Sandoz as a pioneer in the pharmaceutical industry.

Throughout the early 20th century, Sandoz expanded its product portfolio and became known for its commitment to pharmaceutical innovation and quality. The company established itself as one of Switzerland's leading pharmaceutical manufacturers, with products serving diverse therapeutic areas. Sandoz became a trusted brand among healthcare professionals and patients.

In 1996, Sandoz merged with Ciba-Geigy to form Novartis, one of the world's largest pharmaceutical companies. This merger combined two of Switzerland's oldest pharmaceutical traditions and created a global pharmaceutical powerhouse. Following the merger, Sandoz became Novartis's dedicated generics and biosimilars division.

In recent decades, Sandoz grew to become one of the world's largest generic and biosimilar manufacturers. In October 2023, Sandoz completed its spin-off from Novartis and became an independent publicly traded company on the SIX Swiss Exchange (SDZ). As an independent company, Sandoz has continued to grow its biosimilars business, which accounted for 27% of total net sales in Q1 2025, up from 25% in Q1 2023. For the nine months ended September 30, 2025, Sandoz reported net sales of USD 8.057 billion, up 5% at constant currencies.